Asian Currencies Slip as Dollar Holds Firm, Yen Near Four-Decade Low Ahead of Fed, Jobs Data 
SK Holdings, KKR Launch $1.3B Renewable Energy Venture in South Korea 
Northern Star Appoints New CEO as Activist Elliott Pushes for Leadership Overhaul 
Moody’s Says Peru’s President-Elect Keiko Fujimori Could Boost Investor Confidence 
Greece’s Bad Loan Crisis Continues to Limit Credit Access Despite Economic Recovery 
Samsung to Invest $90 Billion in South Korea to Expand AI Chip, Display, and Battery Production 
South Korea Alleges Google Abused Android App Store Dominance, Eyes Major Fine 
OpenAI Proposes 5% U.S. Government Stake Amid AI Policy Talks 
Norway Offshore Oil Workers Reach Wage Deal, Averting Strike 
Kawasaki Heavy Shares Slide on Report of ¥200 Billion Capital Raise Plan 
South Korea Warns Won Is Undervalued, Boosts FX Coordination With Japan 
US Jobs Report Preview: June Payroll Growth Seen Slowing as Fed Rate Decision Looms 
SoftBank’s LY Corp, Bain Raise Kakaku.com Bid to ¥670 Billion, Intensifying Takeover Battle 
South32 Sells Major Aluminium Assets to Alcoa in Deal Worth Up to $5.6 Billion 
Denmark Central Bank Intervenes to Support Krone Peg Against Euro 
Apple Eyes Chinese Memory Chips as AI Shortage Pressures iPhone Supply Chain 
Merck & Co Inc. gets the green light from the Japanese health ministry for its COVID-19 anti-viral pill. The health officials recommended the approval of the said medicine late last week.
The approval of the Merck coronavirus pill is said to be part of the country’s Prime Minister Fumio Kishida’s plan to introduce and distribute new treatments by the end of the year as the growing cases of Omicron variant infection is becoming a very serious concern.
According to Inquirer.net, the committee’s decision has led to the shipments of around 200,000 doses starting this weekend. This is just the preparation and start of the deliveries as per the announcement of the country’s prime minister.
“I am convinced the distribution of this drug is a major step forward for our nation’s COVID–19 handling,” Shigeyuki Goto, Japan’s health minister, told the press after the announcement of the panel’s approval of Merck’s COVID-19 treatment pill.
He added that some of the country’s pharmacies and medical institutions are expected to begin receiving the medicine as early as next Monday. Moreover, it was said that Japan is really laying bets on oral treatments to prevent cases of severe infections and deaths should a sixth wave of the pandemic arise.
Based on the report, Japan agreed to pay $1.2 billion to Merck and its partner Ridgeback Biotherapeutics for the shipment of 1.6 million courses of molnupiravir. PM Kishida also said last week, the government signed a deal for two million doses of another anti-viral treatment pill and this was developed by Pfizer.
In the U.S., health regulators also authorized the use of the Merck pill for some high-risk adult patients. Many countries are now rushing to purchase the said Merck’s molnupiravir due to promising results during trials.
“As a single oral medicine that can be taken at home, early treatment with molnupiravir significantly reduced the risk of hospitalization or death in patients at high risk for progressing to severe COVID-19,” Merck research laboratories president, Dr. Dean Y. Li, said in a press release. “Importantly for patients, there were markedly fewer deaths among those taking molnupiravir in our clinical study and we believe that it will be a critical addition to the measures available to help curb the impact of COVID-19 on patients, healthcare systems, and public health in Japan.”
